AmorChem, KNOCK OUT Event, 5th round

MONTREAL--(BUSINESS WIRE)-- Back by popular demand, AmorChem is hosting its fifth KNOCK OUT Event during the 1^st edition of the EFFERVERSCENCE conference, April 24^th, 2019 in Montreal. Researchers selected to participate in the Dragons’ Den inspired AmorChem KNOCK OUT^TM Event will fight it out in the ring against our panel of “heavyweights” eager to defend their title.

If you are an academic life science researcher with an appetite to KNOCK OUT the competition, if you have innovative science with strong commercial potential, then you may be one of the participants chosen to duke it out in the AmorChem KNOCK OUT Event and could be granted an AmorChem financing of up to $500,000!

Interested researchers must fill out the attached form describing their technology, its clinical applications, its relevance to human disease, as well as its commercial potential. As competition in the ring will be fierce, researchers are encouraged to seek the assistance of their technology transfer or commercialization office that can also prove useful in training for the final Event.

All application forms must be submitted no later than Monday, February 4^th 2019, 5PM at the following email address: info@amorchem.com. Participants chosen to climb into the ring in the final round will be announced no later than March 29^th 2019. They will then become Contenders in the Amorchem KNOCK OUT Event and will be invited to a call in order to assist them in their final preparations.

Contenders will convene on April 24^th, 2019 for the final round. Since 2014, KNOCK OUT has played out in front of a live audience (last year was standing room only!). At the sound of the bell, each Contender will be given up to five minutes to make their case on their technology. Following their pitch, each Contender will duke it out, in the ring, with our “heavyweights” over a ten minute Q&A “boxing match”. The Contenders will confront the “professional boxers” with only wits and scientific agility in their corner. Just as boxers climb into the ring with only their gloves, our contenders will not be allowed visual support.

The champion of this fifth edition of the AmorChem KNOCK OUT Event may qualify for a financing of up to $500,000 from AmorChem, subject to completion of final pre-investment conditions including approval by the AmorChem Investment Committee.

Can you roll with the punches, and go 5 rounds in the ring with our seasoned biotech executives? If you think you can, act fast: spaces will be limited to a maximum of 5 participants and the deadline for application is February 4^th 2019!

This event is supported by our Gold Sponsors: Merck & Co, Fonds de Solidarité des Travailleurs du Québec (FSTQ) and Robic.

About EFFERVESCENCE

EFFERVESCENCE is a major event in the life sciences and health technologies sector in Montreal, its first edition organized by a collective of 15 partners. It provides life sciences researchers, companies and stakeholders with a unique opportunity to network, build business relationships, participate in inspiring conferences, and discover the latest in the industry, everything in an experiential and stimulating environment @ Tohu, Montréal on April 24 and 25, 2019.

About AmorChem

AmorChem (www.amorchem.com) is an early-stage, venture capital fund located in Montreal focused on creating promising life science companies from technologies originating primarily from Quebec-based universities and research centres. Launched in 2011, the AmorChem fund model combines access to financial resources with a virtual incubator structure that enables the rapid development and commercialization of its technologies. The first fund (41.2M$) has built a portfolio of 24 technologies and successfully transacted two pharma exits as well as spun-out five companies. The attractiveness of this seed fund model and the role it plays in the investment ecosystem were highlighted in September 2017 with the launch of the AmorChem II Fund, which now totals $53.7M.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190115005235/en/